Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Opko Health, Inc. |
---|---|
Information provided by: | Opko Health, Inc. |
ClinicalTrials.gov Identifier: | NCT00557791 |
The purpose of this study is to compare the safety and effectiveness of three doses of intravitreal bevasiranib sodium as maintenance therapy for Age-Related Macular Degeneration following initiation of anti-VEGF therapy with three doses of Lucentis®.
Condition | Intervention | Phase |
---|---|---|
Age Related Macular Degeneration |
Drug: Bevasiranib Drug: ranibizumab |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Phase 3, Randomized, Double-Masked, Parallel-Assignment and Dose-Finding Study of Intravitreal Bevasiranib Sodium, Administered Every 8 Weeks as Maintenance Therapy Following Three Injections of Lucentis® Compared With Lucentis® Monotherapy Every 4 Weeks in Patients With Exudative Age-Related Macular Degeneration (AMD). |
Estimated Enrollment: | 496 |
Study Start Date: | November 2009 |
Estimated Study Completion Date: | July 2012 |
Estimated Primary Completion Date: | July 2011 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
A: Active Comparator
Lucentis® (0.5 mg) every 4 weeks.
|
Drug: ranibizumab
Lucentis® (0.5 mg) administered intravitreally every 4 weeks.
|
B: Experimental
Bevasiranib (1.0 mg) every 8 weeks beginning at week 12, after pre-treatment with 3 injections of Lucentis® and initial priming doses of bevasiranib at weeks 2 & 6.
|
Drug: Bevasiranib
Three doses (1.0mg, 2.0mg, 2.5mg) of bevasiranib administered intravitreally every 8 weeks
|
C: Experimental
Bevasiranib (2.0 mg) every 8 weeks beginning at week 12, after pre-treatment with 3 injections of Lucentis® and initial priming doses of bevasiranib at weeks 2 & 6.
|
Drug: Bevasiranib
Three doses (1.0mg, 2.0mg, 2.5mg) of bevasiranib administered intravitreally every 8 weeks
|
D: Experimental
Bevasiranib (2.5 mg) every 8 weeks beginning at week 12, after pre-treatment with 3 injections of Lucentis® and initial priming doses of bevasiranib at weeks 2 & 6.
|
Drug: Bevasiranib
Three doses (1.0mg, 2.0mg, 2.5mg) of bevasiranib administered intravitreally every 8 weeks
|
Ages Eligible for Study: | 50 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Clinical Team | clinicaltrials@opko.com |
Study Director: | Naveed Shams, MD | SVP at Opko Health |
Responsible Party: | Opko Health ( Naveed Shams ) |
Study ID Numbers: | ACU302 |
Study First Received: | November 13, 2007 |
Last Updated: | January 12, 2009 |
ClinicalTrials.gov Identifier: | NCT00557791 |
Health Authority: | United States: Food and Drug Administration |
AMD ARMD Exudative Macular Degeneration Bevasiranib siRNA |
Signs and Symptoms Eye Diseases Retinal Degeneration |
Macular Degeneration Retinal Diseases Retinal degeneration |